Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 8, 2011 Luke Timmerman	Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature?
The Motley Fool December 5, 2011 Brian Orelli	Up 20%, but Uncertainty Still Looms Affymax is still a risky bet.
The Motley Fool May 4, 2007 Mike Havrilla	Taking It to the Affymax Positive clinical data for a potential anemia treatment has the drugmaker's stock on the rise.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.
The Motley Fool December 8, 2011 Brian Orelli	A Soaring Biotech With Room to Run Affymax gets a leg up from an FDA advisory panel vote.
The Motley Fool July 1, 2009 Brian Orelli	The Meat of a One-Drug Wonder AMAG announces that its iron replacement, Feraheme, was approved by the Food and Drug Administration.
The Motley Fool January 7, 2010 Brian Orelli	Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
The Motley Fool May 17, 2007 Brian Lawler	Affymax on the Attack Affymax announces its first-quarter financial results. Investors should pay close attention to the future clinical trial results that Hematide will produce and how Affymax's share price reacts.
The Motley Fool December 10, 2007 Brian Lawler	Amgen Under Review The FDA plans another debate about an Amgen top drug.
The Motley Fool August 26, 2009 Brian Orelli	Amgen Falls Back on the Future Instead of the TREAT trial for Aranesp, Amgen's new cherry is Prolia's potential to treat cancer patients, for which Amgen could get marketing approval next year.
Managed Care June 2007 Martin Sipkoff	Rebates for Anti-Anemia Drugs Draw Response From FDA, CMS Overusing erythropoiesis-stimulating agents to collect rebates can be really bad for the patient. Ripping off taxpayers and private payers is another concern.
The Motley Fool September 10, 2007 Brian Lawler	Get a Glimpse of Amgen's Future Investors will want to pay attention to an FDA advisory panel meeting discussing new labeling recommendations for Amgen's anemia medications. The two drugs represented 44% of the pharmaceutical company's second-quarter revenue.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
The Motley Fool October 7, 2010 Anders Bylund	Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson.
BusinessWeek April 23, 2007 Alex Halperin	Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review.
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
American Family Physician September 1, 2004 Johnson et al.	Clinical Practice Guidelines for Chronic Kidney Disease in Adults: Part I. Definition, Disease Stages, Evaluation, Treatment and Risk Factors Family physicians should weigh the value of the National Kidney Foundation guidelines for their clinical practice based on the strength of evidence and perceived cost-effectiveness until additional evidence becomes available on the usefulness of the recommended quality indicators.
Pharmaceutical Executive February 1, 2007 Jill Wechsler	Washington Report: Bundled Together Democrats and Republicans are making waves over whether government drug-pricing policies also raise concerns about drug safety and treatment practices.
The Motley Fool May 28, 2004 Charly Travers	Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth.
American Family Physician October 15, 2002 Mahesh Krishnan	Preoperative Care of Patients with Kidney Disease Preoperative attention to common medical problems that occur in patients with impaired renal function can lower some surgical risks.
The Motley Fool October 19, 2010 Brian Orelli	When the Status Quo Is a Big Win The lack of an FDA rejection will do just fine. Amgen and Johnson & Johnson seemed to get through the FDA advisory panel process without much problem yesterday.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool August 14, 2009 Brian Orelli	Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel.
The Motley Fool March 17, 2008 Brian Lawler	The Panelling on Amgen's Walls One FDA panel ruling is a win, another is much less upsetting than investors feared.
The Motley Fool January 28, 2010 Brian Orelli	The Next Amgen? Not Yet. Amylin Pharmaceuticals is in much the same situation as Amgen is in: relatively flat sales, and the potential for a nice boost from a Food and Drug Administration approval shortly. But that's where the comparison ends.
The Motley Fool March 25, 2010 Brian Orelli	More Than $5.3 Billion in Revenue Under Attack After dealing with the FDA, Amgen and J&J now have to deal with the Centers for Medicare & Medicaid Services.
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
American Journal of Nursing October 2005 Charlotte Thomas-Hawkins	Self-Management of Chronic Kidney Disease Effective management of this disease requires the patient to be the principal illness manager and this skill requires the nurses guidance and support.
The Motley Fool April 26, 2011 Luke Timmerman	FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex?
The Motley Fool September 6, 2007 Brian Lawler	Amgen's Congressional Helpers Lawmakers push to ease restrictions on anemia compounds from Amgen and Johnson & Johnson. Investors, take note.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
BusinessWeek August 13, 2009 Arlene Weintraub	Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
Pharmaceutical Executive July 30, 2007 Louis A. Morris	Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
BusinessWeek March 22, 2004 Arlene Weintraub	Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?
The Motley Fool September 25, 2007 Brian Lawler	Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note.
Chemistry World June 30, 2014 Phillip Broadwith	Affymax folds after drug withdrawal Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anemia drug Omontys (peginesatide).
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool June 23, 2005 Brian Gorman	Amgen's Drug-Approval Dilemma A recent lawsuit illustrates drugmakers' difficult position. Even conservative drug-stock investors could be in for a bumpy ride.
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
The Motley Fool June 28, 2004 Alyce Lomax	Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
Chemistry World December 6, 2012 Andrew Turley	Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
BusinessWeek November 29, 2004 Carey & Barrett	Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do.